A Composition of matter and Methods of synthesis patent for our advanced compound, PPL-103, was filed in December, 2010 and issued in the US in March, 2015 and has since received patent approval in 12 major countries around the world. Patents also cover Use for treatment of opioid and cocaine addiction therapy as well as pain, and Use for treatment of pain in animals.
Phoenix has obtained an exclusive license from the University of Bath for 25 Nociceptin compounds including BU10038, which we now call PPL-138. A composition of matter patent covering all of the compounds was filed in the US and Europe in December, 2014 and issued in the US in May, 2018 and in Europe in November, 2020. It has been validated in the UK, France, Germany, Spain, Italy, Belgium, Netherlands, and Switzerland.